echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > J INTERN MED: What is the risk of thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica?

    J INTERN MED: What is the risk of thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica?

    • Last Update: 2022-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are systemic inflammatory diseases that primarily affect older women
    .

    The purpose of this study was to compare the risk of thromboembolic events and retinal vascular occlusion in patients with osteoarthritis (OA) with GCA and / or PMR
    .

    Thrombosis _

    In this retrospective study, a total of 1535 patients with GCA, 10265 patients with PMR, and 1203 patients with a combination of the two diseases, and 39009 age- and sex-matched patients with OA were included
    .
    The researchers calculated and assessed the occurrence of pulmonary embolism (PE), deep vein thrombosis (DVT), arterial thromboembolism (ATE), central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) over time rate ratio (IRR)

    .
    We plotted cumulative incidence and calculated hazard ratios for thromboembolic events, adjusting for independent risk factors for thromboembolism

    .

    Patients with GCA and a combination of both diseases had higher IRRs for all thromboembolic events compared with patients with OA
    .
    Patients with comorbidities (HR 2.
    01, 95% CI 1.
    35-2.
    99, p<0.
    001; HR 2.
    37, 95% CI 1.
    23-4.
    53, p=0.
    009) or PMR alone (PMR, respectively) HR was 1.
    89, 95% CI 1.
    50-2.
    41, p<0.
    001; HR was 4.
    68, 95% CI 3.
    10-7.
    07, p<0.
    001, respectively) compared with GCA patients at higher risk of DVT and retinal vascular occlusion

    .
    GCA patients had a higher risk of PE than PMR patients (HR 1.
    55, 95% CI 1.
    1-2.
    18, p=0.
    01)

    .

    CONCLUSIONS: GCA, PMR, and patients with a combination of the two diseases have the same risk of thromboembolic events
    .
    The researchers' findings may help predict the risk of thromboembolic events based on disease phenotype

    .

    Patients with GCA, PMR, and comorbidities had the same risk of thromboembolic events
    .
    The researchers' findings may help predict the risk of thromboembolic events based on disease phenotype

    .

    Original source:

    Original source:

    Despina Michailidou, et al.
    Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States .
    Journal of Internal Medicine.
    2022.
    https://onlinelibrary.
    wiley.
    com/doi/10.
    1111/joim.
    13446

    Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States

    Leave a Comment
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.